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Abstract
©  2017  Khaibullin,  Ivanova,  Martynova,  Cherepnev,  Khabirov,  Granatov,  Rizvanov  and
Khaiboullina. Multiple sclerosis (MS) is an autoimmune neurodegenerative disease characterized
by  chronic  brain  inflammation.  Leukocyte  infiltration  of  brain  tissue  causes  inflammation,
demyelination, and the subsequent formation of sclerotic plaques, which are a hallmark of MS.
Activation of  proinflammatory cytokines is  essential  for  regulation of  lymphocyte migration
across the blood-brain barrier. We demonstrate increased levels of many cytokines, including IL-
2RA,  CCL5,  CCL11,  MIF,  CXCL1,  CXCL10,  IFNγ,  SCF,  and  TRAIL,  were  upregulated  in
cerebrospinal fluid (CSF), whereas IL-17, CCL2, CCL3, CCL4, and IL-12(p40) were activated in MS
serum. Interaction analysis of cytokines in CSF demonstrated a connection between IFNγ and
CCL5 as well as MIF. Many cells can contribute to production of these cytokines including CD8
and  Th1  lymphocytes  and  astrocytes.  Therefore,  we  suggest  that  IFNγ  released  by  Th1
lymphocytes can activate astrocytes, which then produce chemoattractants, including CCL5 and
MIF. These chemokines promote an inflammatory milieu and interact with multiple chemokines
including CCL27 and CXCL1. Of special note, upregulation of CCL27 was found in CSF of MS
cases. This observation is the first to demonstrate CCL27 as a potential contributor of brain
pathology in MS. Our data suggest that CCL27 may be involved in activation and migration of
autoreactive encephalitogenic immune effectors in the brain. Further, our data support the role
of Th1 lymphocytes in the pathogenesis of brain inflammation in MS, with several cytokines
playing a central role.
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